Partners Group Private Equity reported an 8.6% decline in net asset value on a total-return basis for the first half of 2026, as portfolio markdowns outweighed strong distributions to investors.
The London-listed firm distributed approximately EUR 111 million to shareholders during the period, representing about 14% of net assets. Despite the NAV drop, Partners Group returned an additional EUR 35 million through EUR 22 million in dividends and EUR 13 million in share buybacks. Shares closed at EUR 7.08 on August 27, reflecting a 29.6% year-to-date decline and a 38.8% discount to the June 30 NAV of EUR 11.57 per share.
Gross portfolio performance fell 8.3% over the prior 12 months, with four holdings—Pharmathen, USIC, Emeria and Ammega—accounting for -6.4 percentage points of the decline. Pharmathen’s NAV was written down to zero, while USIC represented 1.4% of total NAV, Emeria 6.1% and Ammega 3.5%.
The portfolio’s geographic exposure stood at 44% North America, 45% Europe, 7% Asia-Pacific and 4% Rest of World, with sector allocations led by industrials (28%), information technology (16%) and healthcare (16%). Top 10 holdings comprised roughly 41% of NAV, including DiversiTech (6.8%), Emeria (6.1%) and Vishal Mega Mart (5.7%).
Partners Group maintained a liquidity position of EUR 51 million in cash and EUR 150 million in undrawn revolving credit capacity. The firm targeted a 9.9% dividend yield based on an annual distribution of EUR 0.70 per share, while deploying EUR 13 million selectively during the period.
Average hold period across the portfolio was 4.6 years, with vintage cohorts split between 28% mature (pre-2021), 50% inflection (2021–2023) and 22% young (post-2023). Gross investment multiples varied by vintage, averaging 1.7x for mature holdings, 1.2x for inflection and 1.2x for young investments. Notable exits included Convex Group (2.5x multiple), Galderma (3.5x) and a partial exit of Vishal Mega Mart (8.5x), alongside full exits of Clario (1.5x) and STADA Arzneimittel (2.0x).
Operating metrics for the top 20 portfolio companies showed LTM EBITDA growth of 4.5%, below the historical 13–15% range, with an EV/EBITDA multiple of 16.8x and net debt/EBITDA at 6.9x. AI adoption across 90% of portfolio companies was quantified at over USD 170 million in EBITDA opportunities and USD 2.5 billion in enterprise value potential, with case studies including Version 1 and Foundation Risk Partners reporting a 94% reduction in processing cycle times and a USD 10 million profit impact.
Partners Group also highlighted long-term thematic tailwinds, including projected 20–25% annual growth in data center power demand through 2030 and a global sports economy exceeding USD 1 trillion by 2030. The clean beauty segment was cited as growing at a 15% CAGR, with portfolio company Aroma-Zone achieving 3x revenue growth since 2021.
